X. L. Xu
About
X. L. Xu is a scholar working on Rheumatology, Immunology and Pediatrics, Perinatology and Child Health.
According to data from OpenAlex, X. L. Xu has authored 19 papers receiving a total of 324 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Rheumatology, 10 papers in Immunology and 4 papers in Pediatrics, Perinatology and Child Health. Recurrent topics in X. L. Xu's work include Rheumatoid Arthritis Research and Therapies (8 papers), Psoriasis: Treatment and Pathogenesis (7 papers) and Spondyloarthritis Studies and Treatments (5 papers). X. L. Xu is often cited by papers focused on Rheumatoid Arthritis Research and Therapies (8 papers), Psoriasis: Treatment and Pathogenesis (7 papers) and Spondyloarthritis Studies and Treatments (5 papers). X. L. Xu collaborates with scholars based in United States, United Kingdom and Canada. X. L. Xu's co-authors include G. Lynn Law, Vivian L. MacKay, David Morris, Kyle Serikawa, Eileen Turcott, David R. Goodlett, Mark R. Flory, Lue Ping Zhao, Xiaohong Li and Hookeun Lee and has published in prestigious journals such as Annals of the Rheumatic Diseases, Cell Host & Microbe and Journal of General Virology.
In The Last Decade
X. L. Xu
19 papers receiving 317 citations
Peers
X. L. Xu
Ka Sin Mak Australia
Emilie Evanno France
Maja Studencka‐Turski Germany
Darah Christie Canada
Soizic Bourteele Germany
Daniela Ulgiati Australia
Nicole Regna United States
Adam Mark United States
Citations per year, relative to X. L. Xu X. L. Xu (= 1×)
peers
Ka Sin Mak
Countries citing papers authored by X. L. Xu
Since
Specialization
Citations
This map shows the geographic impact of X. L. Xu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by X. L. Xu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites X. L. Xu more than expected).
Fields of papers citing papers by X. L. Xu
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by X. L. Xu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by X. L. Xu. The network helps show where X. L. Xu may publish in the future.
Co-authorship network of co-authors of X. L. Xu
This figure shows the co-authorship network connecting the top 25 collaborators of X. L. Xu. A scholar is included among the top collaborators of X. L. Xu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with X. L. Xu. X. L. Xu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Wang, Xin, Huihui Kong, Bingxin Chu, et al.. (2024). Identification of a broad-inhibition influenza neuraminidase antibody from pre-existing memory B cells. Cell Host & Microbe. 33(1). 151–166.e8.
2.
Mease, Philip J., M. Shawi, Ya‐Wen Yang, et al.. (2022). AB0892 Targeted Safety Analyses of Guselkumab: Long-Term Results from Randomized Clinical Trials in Patients with Active Psoriatic Arthritis and Moderate to Severe Psoriasis. Annals of the Rheumatic Diseases. 81. 1572–1573.
3.
Nash, Peter, Christopher T. Ritchlin, Proton Rahman, et al.. (2022). POS1070 BASELINE DETERMINANTS OF PAIN RESPONSE IN PATIENTS WITH PSORIATIC ARTHRITIS RECEIVING GUSELKUMAB. Annals of the Rheumatic Diseases. 81. 858–859.
4.
Mease, Philip J., A.B. Gottlieb, Iain B. McInnes, et al.. (2022). POS1035 LOW RATES OF RADIOGRAPHIC PROGRESSION WITH 2 YEARS OF GUSELKUMAB, A SELECTIVE INHIBITOR OF THE INTERLEUKIN-23p19 SUBUNIT: RESULTS FROM A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF BIOLOGIC-NAÏVE PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS. Annals of the Rheumatic Diseases. 81. 831–832.
5.
Coates, Laura C., M. Shawi, Alexa P. Kollmeier, et al.. (2022). POS1017 GUSELKUMAB PROVIDES CONTINUED IMPROVEMENT IN KEY DOMAINS OF PSORIATIC ARTHRITIS THROUGH 2 YEARS. Annals of the Rheumatic Diseases. 81. 818–819.
6.
Siebert, Stefan, Kristen Sweet, Christopher T. Ritchlin, et al.. (2021). POS0195 GUSELKUMAB TREATMENT MODULATES CORE PSORIATIC ARTHRITIS GENE EXPRESSION IN TWO PHASE 3 CLINICAL TRIALS (DISCOVER-1 AND -2). Annals of the Rheumatic Diseases. 80. 312–312.
7.
McInnes, Iain B., Proton Rahman, A.B. Gottlieb, et al.. (2021). POS1027 EFFICACY AND SAFETY OF GUSELKUMAB, A MONOCLONAL ANTIBODY SPECIFIC TO THE p19-SUBUNIT OF INTERLEUKIN-23, THROUGH 2 YEARS: RESULTS FROM A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY CONDUCTED IN BIOLOGIC-NAÏVE PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS. Annals of the Rheumatic Diseases. 80. 783–784.
8.
Gottlieb, Alice B., Joseph F. Merola, April W. Armstrong, et al.. (2021). AB0528 COMPARABLE SAFETY PROFILE OF GUSELKUMAB IN PSORIATIC ARTHRITIS AND PSORIASIS: RESULTS FROM PHASE 3 TRIALS THROUGH 1 YEAR. Annals of the Rheumatic Diseases. 80. 1293–1294.
9.
Rahman, Proton, Christopher T. Ritchlin, Philip Helliwell, et al.. (2020). FRI0359 INTEGRATED SAFETY RESULTS OF TWO PHASE-3 TRIALS OF GUSELKUMAB IN PATIENTS WITH PSORIATIC ARTHRITIS THROUGH THE PLACEBO-CONTROLLED PERIODS. Annals of the Rheumatic Diseases. 79. 776–777.
10.
McInnes, Iain B., Proton Rahman, Alice B. Gottlieb, et al.. (2020). SAT0402 EFFICACY AND SAFETY OF GUSELKUMAB, A MONOCLONAL ANTIBODY SPECIFIC TO THE P19-SUBUNIT OF INTERLEUKIN-23, THROUGH WEEK 52 OF A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY CONDUCTED IN BIOLOGIC-NAÏVE PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS. Annals of the Rheumatic Diseases. 79. 1152–1153.
11.
McGonagle, Dennis, Iain B. McInnes, Atul Deodhar, et al.. (2020). AB0801 EFFECTS OF GUSELKUMAB, A MONOCLONAL ANTIBODY THAT SPECIFICALLY BINDS TO THE P19-SUBUNIT OF INTERLEUKIN-23, ON DACTYLITIS AND ENTHESITIS IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS: POOLED RESULTS THROUGH WEEK 24 FROM TWO PHASE 3 STUDIES. Annals of the Rheumatic Diseases. 79. 1701–1701.
12.
Helliwell, Philip, Dafna D. Gladman, Denis Poddubnyy, et al.. (2020). OP0054 EFFICACY OF GUSELKUMAB, A MONOCLONAL ANTIBODY THAT SPECIFICALLY BINDS TO THE P19-SUBUNIT OF IL-23, ON ENDPOINTS RELATED TO AXIAL INVOLVEMENT IN PATIENTS WITH ACTIVE PSA WITH IMAGING-CONFIRMED SACROILIITIS: WEEK-24 RESULTS FROM TWO PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDIES. Annals of the Rheumatic Diseases. 79. 36–37.
13.
Ritchlin, Christopher T., Philip Helliwell, Wolf‐Henning Boehncke, et al.. (2020). SAT0397 GUSELKUMAB, AN IL-23 INHIBITOR THAT SPECIFICALLY BINDS TO THE IL23P19-SUBUNIT, FOR ACTIVE PSORIATIC ARTHRITIS: ONE YEAR RESULTS OF A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF PATIENTS WHO WERE BIOLOGIC-NAÏVE OR TNFΑ INHIBITOR-EXPERIENCED. Annals of the Rheumatic Diseases. 79. 1148–1149.
14.
Kollmeier, Alexa P., Andrew Greenspan, X. L. Xu, et al.. (2018). Phase 2a, randomized, double‐blind, placebo‐controlled, multicentre, parallel‐group study of an H4R‐antagonist (JNJ ‐39758979) in adults with uncontrolled asthma. Clinical & Experimental Allergy. 48(8). 957–969.
15.
Deodhar, Atul, Alice B. Gottlieb, Wolf‐Henning Boehncke, et al.. (2018). OP0308 Efficacy and safety results of guselkumab in patients with active psoriatic arthritis over 56 weeks from a phase 2a, randomised, double-blind, placebo-controlled study. Annals of the Rheumatic Diseases. 77. 201–201.
16.
Bingham, Clifton O., Steve Bird, Steven S. Smugar, X. L. Xu, & Andrew M. Tershakovec. (2008). Responder analysis and correlation of outcome measures: pooled results from two identical studies comparing etoricoxib, celecoxib, and placebo in osteoarthritis. Osteoarthritis and Cartilage. 16(11). 1289–1293.
17.
MacKay, Vivian L., Xiaohong Li, Mark R. Flory, et al.. (2004). Gene Expression Analyzed by High-resolution State Array Analysis and Quantitative Proteomics. Molecular & Cellular Proteomics. 3(5). 478–489.
18.
Xu, X. L., Leeju C. Wu, Feng Du, et al.. (2001). Inactivation of human SRBC, located within the 11p15.5-p15.4 tumor suppressor region, in breast and lung cancers.. PubMed. 61(21). 7943–9.
19.
Xu, X. L., et al.. (1994). A modified hepatitis B virus surface antigen with the receptor-binding site for hepatocytes at its C terminus: expression, antigenicity and immunogenicity. Journal of General Virology. 75(12). 3673–3677.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Ka Sin Mak Breakdown of academic impact, for papers by Emilie Evanno Breakdown of academic impact, for papers by Louis Philip Benoit Bouvrette Breakdown of academic impact, for papers by Maja Studencka‐Turski Breakdown of academic impact, for papers by Darah Christie Breakdown of academic impact, for papers by M. Soledad Fernández-García Breakdown of academic impact, for papers by Soizic Bourteele Breakdown of academic impact, for papers by Daniela Ulgiati Breakdown of academic impact, for papers by Nicole Regna Breakdown of academic impact, for papers by Adam Mark